Cargando…

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019

Cefiderocol was evaluated by broth microdilution versus 1,050 highly antimicrobial-resistant Pseudomonas aeruginosa clinical isolates from the CANWARD study (2007 to 2019). Overall, 98.3% of isolates remained cefiderocol susceptible (MIC, ≤4 μg/mL), including 97.4% of extensively drug-resistant (XDR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karlowsky, James A., Walkty, Andrew J., Baxter, Melanie R., Adam, Heather J., Lagacé-Wiens, Philippe R. S., Schweizer, Frank, Bay, Denice, Lynch, Joseph P., Mulvey, Michael R., Zhanel, George G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Observation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430561/ https://www.ncbi.nlm.nih.gov/pubmed/35758747 http://dx.doi.org/10.1128/spectrum.01724-22

Ejemplares similares

Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19
por: Golden, Alyssa R., et al.
Publicado: (2022)

2383. In Vitro Activity of Ceftolozane–Tazobactam in Comparison With Ceftazidime–Avibactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates, Including Multidrug-Resistant and Extensively Drug-Resistant Subsets: CANWARD, 2007–2017
por: Walkty, Andrew, et al.
Publicado: (2018)

2813. Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021
por: Walkty, Andrew, et al.
Publicado: (2023)

In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016
por: Walkty, Andrew, et al.
Publicado: (2017)

254 In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 Pseudomonas aeruginosa Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013
por: Walkty, Andrew, et al.
Publicado: (2014)

128. Adequacy of Commonly Prescribed Antimicrobials for Empiric Coverage of Gram-Negative Bacterial Pathogens Recovered from the Bloodstream of Patients Attending Emergency Rooms in Canada: Analysis of Data from the CANWARD Study, 2007 to 2018
por: Walkty, Andrew, et al.
Publicado: (2019)

1216. Presence of the Narrow-Spectrum OXA-1 Beta-lactamase Enzyme Is Associated with Elevated Piperacillin-Tazobactam MIC Values Among ESBL-producing Escherichia coli Clinical Isolates (CANWARD, 2007-2018)
por: Walkty, Andrew, et al.
Publicado: (2021)

In Vitro Activity of Newer Antimicrobials and Relevant Comparators Vs. 349 Stenotrophomonas maltophilia Clinical Isolates Obtained from Patients in Canadian Hospitals (CANWARD, 2011–2016)
por: Walkty, Andrew, et al.
Publicado: (2017)

708. In Vitro Activity of Plazomicin vs. Clinical Isolates of Gram-Negative Bacilli, Including Aminoglycoside Nonsusceptible and Multidrug-Resistant Subsets, Recovered from Patients Across Canada as Part of the CANWARD study, 2011–2018
por: Walkty, Andrew, et al.
Publicado: (2019)

Presence of the narrow-spectrum OXA-1 β-lactamase enzyme is associated with elevated piperacillin/tazobactam MIC values among ESBL-producing Escherichia coli clinical isolates (CANWARD, 2007–18)
por: Walkty, A., et al.
Publicado: (2022)

668. Presence of the Narrow-Spectrum OXA-1 Beta-Lactamase Enzyme is not Associated with Elevated Ceftolozane-Tazobactam MIC Values among ESBL-Producing Escherichia coli Clinical Isolates (CANWARD, 2011-2018)
por: Walkty, Andrew, et al.
Publicado: (2022)

Antimicrobial resistance patterns of bacterial pathogens recovered from the urine of patients at Canadian hospitals from 2009 to 2020
por: Walkty, Andrew, et al.
Publicado: (2022)

Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections
por: Lagacé-Wiens, Philippe, et al.
Publicado: (2014)

Cefiderocol is an effective topical monotherapy for experimental extensively-drug resistant Pseudomonas aeruginosa keratitis
por: Romanowski, Eric G., et al.
Publicado: (2023)

Empyema caused by Clostridium bifermentans: A case report
por: Edagiz, Safa, et al.
Publicado: (2015)

Novel Type III Effectors in Pseudomonas aeruginosa
por: Burstein, David, et al.
Publicado: (2015)

Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa
por: Sadek, Mustafa, et al.
Publicado: (2022)

Osteomyelitis due to multiple carbapenemase-producing Gram-negative bacteria: The first case report of a GES-13-producing Pseudomonas aeruginosa isolate in Canada
por: Sepehri, Shadi, et al.
Publicado: (2014)

Protein Interaction Networks of Catalytically Active and Catalytically Inactive PqsE in Pseudomonas aeruginosa
por: Taylor, Isabelle R., et al.
Publicado: (2022)

Interconnections of Pseudomonas aeruginosa Quorum-Sensing Systems in Intestinal Permeability and Inflammation
por: Singh, Vijay K., et al.
Publicado: (2023)

Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection
por: Zhanel, George G, et al.
Publicado: (2015)

Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis
por: Zhanel, George G., et al.
Publicado: (2016)

Identification of Potential Antimicrobial Targets of Pseudomonas aeruginosa Biofilms through a Novel Screening Approach
por: Valentin, Jules D. P., et al.
Publicado: (2023)

Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations
por: Kufel, Wesley D., et al.
Publicado: (2020)

Pyocyanin-dependent electrochemical inhibition of Pseudomonas aeruginosa biofilms is synergistic with antibiotic treatment
por: Jiménez Otero, Fernanda, et al.
Publicado: (2023)

Volatile Compounds Emitted by Pseudomonas aeruginosa Stimulate Growth of the Fungal Pathogen Aspergillus fumigatus
por: Briard, Benoit, et al.
Publicado: (2016)

In Vitro Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA
por: McElheny, Christi L., et al.
Publicado: (2021)

ABCDs of the Relative Contributions of Pseudomonas aeruginosa Quorum Sensing Systems to Virulence in Diverse Nonvertebrate Hosts
por: Vasquez-Rifo, Alejandro, et al.
Publicado: (2022)

Engineered Superinfective Pf Phage Prevents Dissemination of Pseudomonas aeruginosa in a Mouse Burn Model
por: Prokopczuk, Federico I., et al.
Publicado: (2023)

Combination of phage therapy and cefiderocol to successfully treat Pseudomonas aeruginosa cranial osteomyelitis
por: Simner, Patricia J., et al.
Publicado: (2022)

Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa
por: Macho, Markéta, et al.
Publicado: (2022)

Characterization of Extensively Drug-Resistant (XDR) Carbapenemase-Producing Enterobacterales (CPE) in Canada from 2019 to 2020
por: Bartoszko, Jessica J., et al.
Publicado: (2022)

P44 Nosocomial neurosurgical meningitis due to XDR Pseudomonas aeruginosa: clinical experience with cefiderocol
por: Stevenson, D. R., et al.
Publicado: (2022)

Emergence of an Extensive Drug Resistant Pseudomonas aeruginosa Strain of Chicken Origin Carrying bla(IMP-45), tet(X6), and tmexCD3-toprJ3 on an Inc(pRBL16) Plasmid
por: Dong, Ning, et al.
Publicado: (2022)

The Pseudomonas aeruginosa Exopolysaccharide Psl Facilitates Surface Adherence and NF-κB Activation in A549 Cells
por: Byrd, Matthew S., et al.
Publicado: (2010)

Tracking Polymicrobial Metabolism in Cystic Fibrosis Airways: Pseudomonas aeruginosa Metabolism and Physiology Are Influenced by Rothia mucilaginosa-Derived Metabolites
por: Gao, Bei, et al.
Publicado: (2018)

Successful use of prolonged cefiderocol monotherapy for the treatment of a complex pleural abscess caused by extensively drug-resistant (XDR) Pseudomonas aeruginosa
por: Brookfield, Charlotte, et al.
Publicado: (2023)

Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa
por: Chavda, A, et al.
Publicado: (2021)

Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2021)

Quantitative Visualization of Gene Expression in Mucoid and Nonmucoid Pseudomonas aeruginosa Aggregates Reveals Localized Peak Expression of Alginate in the Hypoxic Zone
por: Jorth, Peter, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_km9v2t0cgkvfqs6iv9cfanpg6s